Skip to main content

Advertisement

Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Safety, tolerability and immunogenicity of V934/V935 hTERT vaccination in cancer patients with selected solid tumors: a phase I study

Fig. 3

Cell-mediated immune response to hTERT peptide pool 2 for the most frequent tumor types. Cell-mediated immunity response to hTERT pool 2 increased significantly (p < 0.01) in prostate cancer patients. No statistically significant response was observed in other tumor types (here malignant melanoma patients are pooled together with melanoma patients)

Back to article page